Yonsei Med J.  2005 Dec;46(6):779-787.

Polymorphism of the ACE Gene in Dialysis Patients: Overexpression of DD Genotype in Type 2 Diabetic End-Stage Renal Failure Patients

• Park HC
• Choi SR
• Kim BS
• Lee TH
• Kang BS
• Choi KH
• Lee HY
• Han DS
• Ha SK

Abstract

The angiotensin-converting enzyme (ACE) gene DD homozygote has been suggested to be a significant risk factor for the progression of diabetic nephropathy. We analyzed clinical parameters and ACE genotype distribution between type 2 diabetic patients at the extremes of renal risk, i.e. an end-stage renal failure (ESRF) group (n = 103, group 1) who were on dialysis therapy due to progression of diabetic nephropathy, and a no progression group (n = 88, group 2) who had maintained normal renal function and normoalbuminuria for more than 15 years. There were no significant differences in age, sex, body mass index, HbA1c level, or lipid profiles between the two groups (p > 0.05). Group 1 had a significantly higher prevalence of hypertension [group 1: 82.5% (85/103) vs. group 2: 50.0% (44/88), p < 0.05] and diabetic retinopathy [group 1: 103/103 (100%) vs. group 2: 28/88 (31.8%), p < 0.05] than group 2. Daily urinary albumin excretion was also higher in group 1 than in group 2 [group 1: 2873 +/- 2176 mg/day vs. 12 +/- 7 g/day, p < 0.05]. The frequencies of the DD, ID, and II genotypes of the ACE gene in group 1 and group 2 were 26.2%, 47.6%, and 26.2%, and 7.9%, 57.9%, and 34.2%, respectively. The ACE genotype frequencies between the two groups were significantly different according to a chi-square test with Bonferroni's correction (p = 0.004). The presence of the DD genotype increased the risk of ESRF 4.286-fold compared to the II genotype [odds ratio 4.286, 95% CI 1.60- 11.42, p = 0.005]. The frequency of the D-allele was higher in both male and female patients in group 1 compared to group 2, but reached statistical significance only in males [male, group 1: 50.8% vs. group 2: 35.0%, p = 0.018, female, group 1: 48.8% vs. group 2: 39.5%, p = 0.231]. This study, although limited by sample size, showed that type 2 diabetic ESRF patients more frequently expressed the DD genotype. These findings may substantiate the previously noted relationship between the ACE DD genotype and the progression of diabetic nephropathy in Korean type 2 diabetic patients.

Keyword

ACE gene polymorphism; end-stage renal failure; type 2 diabetes

MeSH Terms

Renal Dialysis
*Polymorphism, Genetic
Peptidyl-Dipeptidase A/*genetics/metabolism
Middle Aged
Male
Kidney Failure, Chronic/diagnosis/*genetics
Humans
Homozygote
Gene Frequency
Female
Diabetic Nephropathies/diagnosis/*genetics
Diabetes Mellitus, Type 2/diagnosis/*genetics
Aged

Reference

1. Tarnow L. Genetic pattern in diabetic nephropathy. Nephrol Dial Transplant. 1996. 11:410–412.

2. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence of genetic susceptibility to diabetic nephropathy. N Engl J Med. 1989. 320:1161–1165.

3. Borsch-Johnsen K, Norgaard K, Hommel E, Mathiesen ER, Jensen JS, Deckert T, et al. Is diabetic nephropathy an inherited complication? Kidney Int. 1992. 41:719–722.

4. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1990. 33:438–443.

5. Freedman BI, Tuttle AB, Spray BJ. Familial predisposition to nephropathy in African-Americans with non-insulin dependent diabetes mellitus. Am J Kidney Dis. 1995. 25:710–713.

6. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993. 329:1456–1462.

7. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001. 345:851–860.

8. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001. 345:861–869.

9. Taal MW. Angiotensin-converting enzyme gene polymorphisms in renal disease: clinically relevant? Curr Opin Nephrol Hypertens. 2000. 9:651–657.

10. Marre M, Bernadet P, Gallois Y, Savagner F, Guyene TT, Hallab M, et al. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes. 1994. 43:384–388.

11. Kunz R, Bork JP, Fritsche L, Ringel J, Sharma AM. Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: a methodologic appraisal and systemic review. J Am Soc Nephrol. 1998. 9:1653–1663.

12. Grimm R, Rettig R. Association studies between the angiotensin-converting enzyme insertion/deletion polymorphism and hypertension: still interesting. J Hypertens. 2002. 20:1049–1051.

13. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990. 86:1343–1346.

14. Danser AH, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR, Riegger GA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation. 1995. 92:1387–1388.

15. Yoshida H, Kuriyama S, Atsumi Y, Tomonari H, Mitarai T, Hamaguchi A, et al. Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus. Kidney Int. 1996. 50:657–664.

16. Ha SK, Park HC, Park HS, Kang BS, Lee TH, Hwang HJ, et al. ACE gene polymorphism and progression of diabetic nephropathy in Korean type 2 diabetic patients: effect of ACE gene DD on the progression of diabetic nephropathy. Am J Kidney Dis. 2003. 41:943–949.

17. Schmidt S, Strojek K, Grzeszczak W, Bergis K, Ritz E. Excess of DD homozygotes in haemodialysed patients with type II diabetes. The Diabetic Nephropathy Study Group. Nephrol Dial Transplant. 1997. 12:427–429.

18. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003. 26:3160–3167.

19. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992. 51:197–205.

20. Ha SK, Seo JK. Insertion/deletion polymorphism in ACE gene as a predictor for progression of diabetic nephropathy. Kidney Int Suppl. 1997. 52:S28–S32.

21. Fujisawa T, Ikegami H, Kawaguchi Y, Hamada Y, Ueda H, Shintani M, et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia. 1998. 41:47–53.

22. Kunz R, Bork JP, Fritsche L, Ringel J, Sharma AM. Association between the angiotensin-converting enzyme insertion/deletion polymorphism and diabetic nephropathy: a methodologic appraisal and systemic review. J Am Soc Nephrol. 1998. 9:1653–1663.

23. Tarnow L, Gluud C, Parving HH. Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant. 1998. 13:1125–1130.

24. Parving HH, Mauer M, Ritz E. Brenner BM, editor. Diabetic nephropathy. Brenner and Rector's The Kidney. 2004. 7th ed. Philadelphia, PA: WB Saunders;1777–1805.

25. Wong TY, Chan JC, Poon E, Li PK. Lack of association of angiotensin-converting enzyme (DD/II) and angiotensinogen M235T gene polymorphism with renal function among Chinese patients with type II diabetes. Am J Kidney Dis. 1999. 33:1064–1070.

26. Bjorck S, Blohme G, Sylven C, Mulec H. Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy. Nephrol Dial Transplant. 1997. 12:Suppl 2. 67–70.

27. Schmidt S, Ritz E. Angiotensin I converting enzyme gene polymorphism and diabetic nephropathy in type II diabetes. Nephrol Dial Transplant. 1997. 12:37–41.

28. Vleming LJ, van der Pijl JW, Lemkes HH, Westendorp RG, Maassen JA, Daha MR, et al. The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM. Clin Nephrol. 1999. 51:133–140.

29. Lovati E, Richard R, Frey BM, Frey FJ, Ferrari P. Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease. Kidney Int. 2001. 60:46–54.

30. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L, et al. Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. Diabetologia. 1995. 38:798–803.

31. Sakka Y, Babazono T, Sato A, Ujihara N, Iwamoto Y. ACE gene polymorphism, left ventricular geometry, and mortality in diabetic patients with end-stage renal disease. Diabetes Res Clin Pract. 2004. 64:41–49.

32. Seliger SL, Davis C, Stehman-Breen C. Gender and the progression of renal disease. Curr Opin Nephrol Hypertens. 2001. 10:219–225.

33. Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol. 2000. 11:319–329.

34. Silbiger SR, Neugarten J. The impact of gender on the progression of chronic renal disease. Am J Kidney Dis. 1995. 25:515–533.

35. Savage S, Nagel NJ, Estacio RO, Lukken N, Schrier RW. Clinical factors associated with urinary albumin excretion in type II diabetes. Am J Kidney Dis. 1995. 25:836–844.

36. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 1998. 158:998–1004.

37. Garza R, Medina R, Basu S, Pugh JA. Predictors of the rate of renal function decline in non-insulin-dependent diabetes mellitus. Am J Nephrol. 1997. 17:59–67.

38. Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res. 2002. 53:672–677.